Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4282 - Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Clinical Research

Tumour Site

Colon and Rectal Cancer

Presenters

Anne Flament

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

A. Flament1, A. Hendlisz2, L. Shaza2, S. Aspeslagh2, M. Vouche3, V. Donckier3, A. Awada2, J. Machiels4, M. van den Eynde4, J. Canon5, J. Carrasco6, C. Lonez1, F.F. Lehmann1

Author affiliations

  • 1 Clinical Development, Celyad SA, 1435 - Mont Saint Guibert/BE
  • 2 Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, 1000 - Brussels/BE
  • 3 Department Of Radiology, Institut Jules Bordet, Université Libre de Bruxelles, 1000 - Brussels/BE
  • 4 Oncology, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
  • 5 4. service D’oncologie-hématologie, Site Notre-dame, Grand Hopital de Charleroi Site Notre Dame, 6000 - Charleroi/BE
  • 6 Medical Oncology, Grand Hopital de Charleroi Site Notre Dame, 6000 - Charleroi/BE
More

Resources

Abstract 4282

Background

Chimeric antigen receptor T-cell (CAR-Ts) therapies have yet to demonstrate positive results in the context of solid tumors likely because of the inability of classical CAR-Ts to infiltrate into the tumor and overcome the hostile immune suppressive tumor microenvironment (TME). CYAD-01, a NKG2D receptor-based CAR-T, is currently evaluated in the ongoing THINK study (NCT03018405) without preconditioning therapy in both hematologic and solid indications, and demonstrated encouraging signs of clinical stabilization in refractory metastatic colorectal (mCRC) and ovarian cancer patients. These preliminary results prompted us to design a clinical development plan evaluating CYAD-01 in multiple settings.

Trial design

To improve the likeliness to observe clinical activity of CYAD-01 in metastatic solid tumors, the SHRINK (NCT03310008) and the LINK (NCT03370198) trials have been designed to address, respectively, the challenge related to the immunosuppressive TME and difficulty of CAR-T cells to access the site of metastases. The SHRINK trial is evaluating the multiple infusion CYAD-01 treatment i.v. administered concurrently to a standard-of-care FOLFOX neoadjuvant treatment for the treatment of mCRC disease with potentially resectable liver metastases, with the aim to (i) favor infiltration into the immunosuppressive TME but also (ii) provide an opportunity for the CYAD-01 cells to better engraft due to the lymphodepletion induced by the FOLFOX, and likely (iii) increase the NKG2D ligand expression in tumor tissues targeted by CYAD-01. The LINK trial is evaluating multiple hepatic transarterial administrations of CYAD-01 in mCRC patients with unresectable liver metastases with the potential advantage of a lower systemic toxicity and higher and more persistent concentration of the infused cells on the TME compared to systemic administration and difference in blood supply between uninvolved liver parenchyma and metastases. Finally, the boosting of the adaptive immune response by CYAD-01 might control distant lesions due to a possible abscopal effect. Both studies were initiated in 2018 and the first patients were successfully enrolled.

Clinical trial identification

NCT03310008, EudraCT: 2017-000616-41; NCT03370198, EudraCT 2017-000959-11.

Legal entity responsible for the study

Celyad SA.

Funding

Celyad SA.

Editorial Acknowledgement

Disclosure

A. Flament, F.F. Lehmann, C. Lonez: Employee: Celyad SA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.